miR‑802 inhibits the aggressive behaviors of non‑small cell lung cancer cells by directly targeting FGFR1

  • Authors:
    • Jiexia Zhang
    • Jun Li
    • Shiyue Li
    • Chengzhi Zhou
    • Yinyin Qin
    • Xiaoxiang Li
  • View Affiliations

  • Published online on: March 29, 2019     https://doi.org/10.3892/ijo.2019.4765
  • Pages: 2211-2221
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Emerging reports have revealed that several microRNAs (miRNAs) are abnormally expressed in non‑small cell lung cancer (NSCLC). miRNAs have been identified as oncogenes or tumor suppressors, and regulate various biological processes including oncogenesis and development. miR‑802 is dysregulated in multiple types of human cancer, and exerts tumor‑suppressive or promoting roles. However, the expression levels and functional roles of miR‑802 in NSCLC remain largely unknown. In the present study, miR‑802 expression was demonstrated to be decreased in NSCLC tissues and cell lines. A low miR‑802 expression was significantly correlated with the tumor stage, lymph node metastasis and brain metastasis in NSCLC patients. Restoring miR‑802 expression inhibited NSCLC cell proliferation and colony formation, induced cell apoptosis, decreased cell migration and invasion in vitro, and hindered in vivo tumor growth. Mechanistically, fibroblast growth factor receptor 1 (FGFR1) was confirmed as the target gene of miR‑802 in NSCLC cells. In addition, FGFR1 silencing mimicked the tumor‑suppressing roles of miR‑802 upregulation in NSCLC cells. Furthermore, rescue experiments revealed that FGFR1 reintroduction rescued the miR‑802‑induced inhibition of the malignant phenotypes in NSCLC cells. Notably, miR‑802 was able to deactivate the phosphoinositide 3‑kinase (PI3K)/AKT serine/threonine kinase (Akt)/mammalian target of rapamycin (mTOR) pathway in NSCLC cells in vitro and in vivo. Overall, these results demonstrated that miR‑802 could downregulate FGFR1 expression, thereby deactivating the PI3K/Akt/mTOR pathway and inhibiting the malignant development of NSCLC. Thus, miR‑802 may be a therapeutic candidate for patients with NSCLC.

References

1 

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI

3 

Fiteni F, Anota A, Westeel V and Bonnetain F: Methodology of health-related quality of life analysis in phase III advanced non-small-cell lung cancer clinical trials: A critical review. BMC Cancer. 16:1222016. View Article : Google Scholar : PubMed/NCBI

4 

Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D’Amico TA, Demmy TL, Ganti AK, et al NCCN Non-Small Cell Lung Cancer Panel Members: Non-small cell lung cancer. J Natl Compr Canc Netw. 8:740–801. 2010. View Article : Google Scholar : PubMed/NCBI

5 

Zarogoulidis K, Zarogoulidis P, Darwiche K, Boutsikou E, Machairiotis N, Tsakiridis K, Katsikogiannis N, Kougioumtzi I, Karapantzos I, Huang H, et al: Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis. 5(Suppl 4): S389–S396. 2013.PubMed/NCBI

6 

Schabath MB, Nguyen A, Wilson P, Sommerer KR, Thompson ZJ and Chiappori AA: Temporal trends from 1986 to 2008 in overall survival of small cell lung cancer patients. Lung Cancer. 86:14–21. 2014. View Article : Google Scholar : PubMed/NCBI

7 

Li Z, Song Y, Liu L, Hou N, An X, Zhan D, Li Y, Zhou L, Li P, Yu L, et al: miR-199a impairs autophagy and induces cardiac hypertrophy through mTOR activation. Cell Death Differ. 24:1205–1213. 2017. View Article : Google Scholar :

8 

Mao M, Wu Z and Chen J: MicroRNA-187-5p suppresses cancer cell progression in non-small cell lung cancer (NSCLC) through down-regulation of CYP1B1. Biochem Biophys Res Commun. 478:649–655. 2016. View Article : Google Scholar : PubMed/NCBI

9 

Kim VN: MicroRNA biogenesis: Coordinated cropping and dicing. Nat Rev Mol Cell Biol. 6:376–385. 2005. View Article : Google Scholar : PubMed/NCBI

10 

Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI

11 

Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI

12 

Aigner A: MicroRNAs (miRNAs) in cancer invasion and metastasis: Therapeutic approaches based on metastasis-related miRNAs. J Mol Med (Berl). 89:445–457. 2011. View Article : Google Scholar

13 

Rottiers V and Näär AM: MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol. 13:239–250. 2012. View Article : Google Scholar : PubMed/NCBI

14 

Cho WC: MicroRNAs: Potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol. 42:1273–1281. 2010. View Article : Google Scholar

15 

Bienertova-Vasku J, Sana J and Slaby O: The role of microRNAs in mitochondria in cancer. Cancer Lett. 336:1–7. 2013. View Article : Google Scholar : PubMed/NCBI

16 

Bouyssou JM, Manier S, Huynh D, Issa S, Roccaro AM and Ghobrial IM: Regulation of microRNAs in cancer metastasis. Biochim Biophys Acta. 1845:255–265. 2014.PubMed/NCBI

17 

Lang Y, Xu S, Ma J, Wu J, Jin S, Cao S and Yu Y: MicroRNA-429 induces tumorigenesis of human non-small cell lung cancer cells and targets multiple tumor suppressor genes. Biochem Biophys Res Commun. 450:154–159. 2014. View Article : Google Scholar : PubMed/NCBI

18 

Wang K, Dong L, Fang Q, Xia H and Hou X: Low serum miR-98 as an unfavorable prognostic biomarker in patients with non-small cell lung cancer. Cancer Biomark. 20:283–288. 2017. View Article : Google Scholar : PubMed/NCBI

19 

Wang L, Qu J, Zhou L, Liao F and Wang J: MicroRNA-373 Inhibits Cell Proliferation and Invasion via Targeting BRF2 in Human Non-small Cell Lung Cancer A549 Cell Line. Cancer Res Treat. 50:936–949. 2018. View Article : Google Scholar :

20 

Li T, Ding ZL, Zheng YL and Wang W: MiR-484 promotes non-small-cell lung cancer (NSCLC) progression through inhibiting Apaf-1 associated with the suppression of apoptosis. Biomed Pharmacother. 96:153–164. 2017. View Article : Google Scholar : PubMed/NCBI

21 

Jiang W, Wei K, Pan C, Li H, Cao J, Han X, Tang Y, Zhu S, Yuan W, He Y, et al: MicroRNA-1258 suppresses tumour progression via GRB2/Ras/Erk pathway in non-small-cell lung cancer. Cell Prolif. 51:e125022018. View Article : Google Scholar : PubMed/NCBI

22 

Lu J, Zhan Y, Feng J, Luo J and Fan S: MicroRNAs associated with therapy of non-small cell lung cancer. Int J Biol Sci. 14:390–397. 2018. View Article : Google Scholar : PubMed/NCBI

23 

Zhou Q, Huang SX, Zhang F, Li SJ, Liu C, Xi YY, Wang L, Wang X, He QQ, Sun CC, et al: MicroRNAs: A novel potential biomarker for diagnosis and therapy in patients with non-small cell lung cancer. Cell Prolif. 50:502017. View Article : Google Scholar

24 

Florczuk M, Szpechcinski A and Chorostowska-Wynimko J: miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives. Target Oncol. 12:179–200. 2017. View Article : Google Scholar : PubMed/NCBI

25 

Wang D, Lu G, Shao Y and Xu D: microRNA-802 inhibits epithelial-mesenchymal transition through targeting flotillin-2 in human prostate cancer. Biosci Rep. 37:372017. View Article : Google Scholar

26 

Wu X, Gong Z, Sun L, Ma L and Wang Q: MicroRNA-802 plays a tumour suppressive role in tongue squamous cell carcinoma through directly targeting MAP2K4. Cell Prolif. 50:502017. View Article : Google Scholar

27 

Yuan F and Wang W: MicroRNA-802 suppresses breast cancer proliferation through downregulation of FoxM1. Mol Med Rep. 12:4647–4651. 2015. View Article : Google Scholar : PubMed/NCBI

28 

Zhang XY, Mu JH, Liu LY and Zhang HZ: Upregulation of miR-802 suppresses gastric cancer oncogenicity via targeting RAB23 expression. Eur Rev Med Pharmacol Sci. 21:4071–4078. 2017.PubMed/NCBI

29 

Cao ZQ, Shen Z and Huang WY: MicroRNA-802 promotes osteosarcoma cell proliferation by targeting p27. Asian Pac J Cancer Prev. 14:7081–7084. 2013. View Article : Google Scholar

30 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar

31 

Volm M, Koomägi R, Mattern J and Stammler G: Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas. Eur J Cancer. 33:691–693. 1997. View Article : Google Scholar : PubMed/NCBI

32 

Tran TN, Selinger CI, Kohonen-Corish MR, McCaughan BC, Kennedy CW, O’Toole SA and Cooper WA: Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer. Lung Cancer. 81:462–467. 2013. View Article : Google Scholar : PubMed/NCBI

33 

Tan Q, Wang Z, Wang Q, Wang Y, Huang Z, Su N, Jin M, Kuang L, Qi H, Ni Z, et al: A novel FGFR1-binding peptide exhibits anti-tumor effect on lung cancer by inhibiting proliferation and angiogenesis. Int J Biol Sci. 14:1389–1398. 2018. View Article : Google Scholar : PubMed/NCBI

34 

Yuan H, Li ZM, Shao J, Ji WX, Xia W and Lu S: FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells. J Exp Clin Cancer Res. 36:722017. View Article : Google Scholar : PubMed/NCBI

35 

Ji W, Yu Y, Li Z, Wang G, Li F, Xia W and Lu S: FGFR1 promotes the stem cell-like phenotype of FGFR1-amplified non-small cell lung cancer cells through the Hedgehog pathway. Oncotarget. 7:15118–15134. 2016.PubMed/NCBI

36 

Schultheis AM, Bos M, Schmitz K, Wilsberg L, Binot E, Wolf J, Büttner R and Schildhaus HU: Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small-cell lung cancer. Mod Pathol. 27:214–221. 2014. View Article : Google Scholar

37 

Mano Y, Takahashi K, Ishikawa N, Takano A, Yasui W, Inai K, Nishimura H, Tsuchiya E, Nakamura Y and Daigo Y: Fibroblast growth factor receptor 1 oncogene partner as a novel prognostic biomarker and therapeutic target for lung cancer. Cancer Sci. 98:1902–1913. 2007. View Article : Google Scholar : PubMed/NCBI

38 

Hu P, Chen H, McGowan EM, Ren N, Xu M and Lin Y: Assessment of FGFR1 Over-Expression and Over-Activity in Lung Cancer Cells: A Toolkit for Anti-FGFR1 Drug Screening. Hum Gene Ther Methods. 29:30–43. 2018. View Article : Google Scholar

39 

Liu H, Ma Y, Liu C, Li P and Yu T: Reduced miR-125a-5p level in non-small-cell lung cancer is associated with tumour progression. Open Biol. 8:82018. View Article : Google Scholar

40 

Xu BB, Gu ZF, Ma M, Wang JY and Wang HN: MicroRNA-590-5p suppresses the proliferation and invasion of non-small cell lung cancer by regulating GAB1. Eur Rev Med Pharmacol Sci. 22:5954–5963. 2018.PubMed/NCBI

41 

Yang D, Li JS, Xu QY, Xia T and Xia JH: Inhibitory Effect of MiR-449b on Cancer Cell Growth and Invasion through LGR4 in Non-Small-Cell Lung Carcinoma. Curr Med Sci. 38:582–589. 2018. View Article : Google Scholar : PubMed/NCBI

42 

Jiang M, Li X, Quan X, Li X and Zhou B: Clinically Correlated MicroRNAs in the Diagnosis of Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. BioMed Res Int. 2018:59309512018. View Article : Google Scholar : PubMed/NCBI

43 

Turner CA, Calvo N, Frost DO, Akil H and Watson SJ: The fibroblast growth factor system is downregulated following social defeat. Neurosci Lett. 430:147–150. 2008. View Article : Google Scholar

44 

Devilard E, Bladou F, Ramuz O, Karsenty G, Dalès JP, Gravis G, Nguyen C, Bertucci F, Xerri L and Birnbaum D: FGFR1 and WT1 are markers of human prostate cancer progression. BMC Cancer. 6:2722006. View Article : Google Scholar : PubMed/NCBI

45 

Schäfer MH, Lingohr P, Sträßer A, Lehnen NC, Braun M, Perner S, Höller T, Kristiansen G, Kalff JC and Gütgemann I: Fibroblast growth factor receptor 1 gene amplification in gastric adenocarcinoma. Hum Pathol. 46:1488–1495. 2015. View Article : Google Scholar : PubMed/NCBI

46 

Göke F, Göke A, von Mässenhausen A, Franzen A, Sharma R, Kirsten R, Böhm D, Kristiansen G, Stenzinger A, Wynes M, et al: Fibroblast growth factor receptor 1 as a putative therapy target in colorectal cancer. Digestion. 88:172–181. 2013. View Article : Google Scholar : PubMed/NCBI

47 

Cheng CL, Thike AA, Tan SY, Chua PJ, Bay BH and Tan PH: Expression of FGFR1 is an independent prognostic factor in triple-negative breast cancer. Breast Cancer Res Treat. 151:99–111. 2015. View Article : Google Scholar : PubMed/NCBI

48 

Miao JL, Liu RJ, Zhou JH and Meng SH: Fibroblast Growth Factor Receptor 1 Gene Amplification in Nonsmall Cell Lung Cancer. Chin Med J (Engl). 129:2868–2872. 2016. View Article : Google Scholar

Related Articles

Journal Cover

June 2019
Volume 54 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Zhang, J., Li, J., Li, S., Zhou, C., Qin, Y., & Li, X. (2019). miR‑802 inhibits the aggressive behaviors of non‑small cell lung cancer cells by directly targeting FGFR1. International Journal of Oncology, 54, 2211-2221. https://doi.org/10.3892/ijo.2019.4765
MLA
Zhang, J., Li, J., Li, S., Zhou, C., Qin, Y., Li, X."miR‑802 inhibits the aggressive behaviors of non‑small cell lung cancer cells by directly targeting FGFR1". International Journal of Oncology 54.6 (2019): 2211-2221.
Chicago
Zhang, J., Li, J., Li, S., Zhou, C., Qin, Y., Li, X."miR‑802 inhibits the aggressive behaviors of non‑small cell lung cancer cells by directly targeting FGFR1". International Journal of Oncology 54, no. 6 (2019): 2211-2221. https://doi.org/10.3892/ijo.2019.4765